

7-5/2013/EU/WC-0213
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi- 110 002.

Dated: **27 JUN 2019**

To,

**M/s Laurus Labs Limited (Unit-1),
Plot No.21, Jawaharlal Nehru Pharma City,
Parwada, Visakhapatnam District -531021,
Andhra Pradesh, India.**

Sub: - Written Confirmation of M/s Laurus Labs Limited (Unit-1), Plot No.21, Jawaharlal Nehru Pharma City, Parwada, Visakhapatnam District -531021, Andhra Pradesh, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b (2) (b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application submitted to CDSCO, Hyderabad Zonal office and the recommendation received from DDC (I), Hyderabad Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the event of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

| Annexure No. | No. of Products | Date of issue | Valid up to |
|--------------|-----------------|---------------|-------------|
| 01. | 37 | 27 JUN 2019 | 02.07. 2022 |
| 02. | 10 | 27 JUN 2019 | 02.07 .2022 |

Yours faithfully,

(Dr.S.Eswara Reddy)
Drugs Controller General (India).

w/c EDCL
19/06/19

f-2
24-6-19

adh
25/06/19



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Laurus Labs Limited (Unit-1),
Plot No.21, Jawaharlal Nehru Pharma City,
Parwada, Visakhapatnam District -531021,
Andhra Pradesh, India

2. Manufacturer's license number: 05/VP/AP/2008/B/CC

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

As per List enclosed

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 18/06/2018 and 19/06/2018

The Written Confirmation remains valid until: 02nd July, 2022.

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India.

Name and function of responsible person: Dr. S. Eswara Reddy.
Drugs Controller General (India).

E-mail:

Telephone no.:

Fax no.:

dcg@nic.in,

+91-11-23236965

+91-11-23236973

Signature

% SDCS
19/06/19

25/06/19



Stamp of the authority and date

27 JUN 2019



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

WC-0213

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s Laurus Labs Limited (Unit-1),
Plot No.21, Jawaharlal Nehru Pharma City,
Parwada, Visakhapatnam District -531021,
Andhra Pradesh, India.

List of APIs:

| S. No. | Active substance(s) | Activity(ies) |
|--------|--|-------------------------|
| 1. | Abacavir IH | Manufacturing & Packing |
| 2. | Abacavir Sulfate USP/Ph. Int./IH/Ph.Eur. | Manufacturing & Packing |
| 3. | Atazanavir Sulphate IH | Manufacturing & Packing |
| 4. | Atropine Sulphate USP/Ph. Eur. | Manufacturing & Packing |
| 5. | Bortezomib IH | Manufacturing & Packing |
| 6. | Canagliflozin IH | Manufacturing & Packing |
| 7. | Cabazitaxel IH | Manufacturing & Packing |
| 8. | Capecitabine USP/IP | Manufacturing & Packing |
| 9. | Carfilzomib IH | Manufacturing & Packing |
| 10. | Clopidogrel Hydrogen Sulphate Ph.Eur | Manufacturing & Packing |
| 11. | Dabigatran Etxilate Mesylate IH | Manufacturing & Packing |
| 12. | Daclatasvir Dihydrochloride IH | Manufacturing & Packing |
| 13. | Darunavir IH | Manufacturing & Packing |
| 14. | Darunavir Ethanolate IH | Manufacturing & Packing |
| 15. | Docetaxel anhydrous IP/IH/Ph.Eur | Manufacturing & Packing |
| 16. | Dolutegravir Sodium IH | Manufacturing & Packing |
| 17. | Efavirenz USP/IH/Ph.Int | Manufacturing & Packing |
| 18. | Emtricitabine Ph. Int./IH | Manufacturing & Packing |
| 19. | Erlotinib Hydrochloride IH | Manufacturing & Packing |
| 20. | Feibamate USP/IH | Manufacturing & Packing |
| 21. | Gemcitabine Hydrochloride USP/Ph. Eur. /BP/IH | Manufacturing & Packing |
| 22. | Hydroxy Chlorquine Sulfate USP | Manufacturing & Packing |
| 23. | Homatropine Methyl Bromide USP/Ph. Eur. | Manufacturing & Packing |
| 24. | Imatinib Mesylate IH | Manufacturing & Packing |
| 25. | Irinotecan HCl Trihydrate USP/IH | Manufacturing & Packing |
| 26. | Lamivudine USP/Ph. Int. /BP/Ph. Eur. | Manufacturing & Packing |
| 27. | Lenalidomide IH | Manufacturing & Packing |



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Laurus Labs Limited (Unit-1),
Plot No.21, Jawaharlal Nehru Pharma City,
Parwada, Visakhapatnam District -531021,
Andhra Pradesh, India.

| S. No. | Active substance(s) | Activity(ies) |
|--------|---|-------------------------|
| 28. | Metformin HCl IP/USP/Ph.Eur/JP/IH | Manufacturing & Packing |
| 29. | Oseltamivir Phosphate IH | Manufacturing & Packing |
| 30. | Pazopanib Hydrochloride IH | Manufacturing & Packing |
| 31. | Pemetrexed Disodium IH | Manufacturing & Packing |
| 32. | Pregabalin Ph.Eur/IH | Manufacturing & Packing |
| 33. | Ritonavir IH/Ph.Eur. | Manufacturing & Packing |
| 34. | Temozolamide USP | Manufacturing & Packing |
| 35. | Tenofovir Disoproxil Fumarate Ph. Int./IH | Manufacturing & Packing |
| 36. | Thalidomide USP/IH | Manufacturing & Packing |
| 37. | Montelukast Sodium USP/IH/Ph. Eur. | Manufacturing & Packing |

ITEM(S) Thirty Seven (37) ONLY

The Written Confirmation remains valid until: 02.07.2022



Signature

Stamp of the authority and date



21 JUN 2019

9/02/19
24/06/19


24-6-19

nd
25/06/19



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Laurus Labs Limited (Unit-1),
Plot No.21, Jawaharlal Nehru Pharma City,
Parwada, Visakhapatnam District -531021,
Andhra Pradesh, India.

List of APIs:

| S. No. | Active substance(s) | Activity(ies) |
|--------|-----------------------------------|-------------------------|
| 1. | Azacitidine IH | Manufacturing & Packing |
| 2. | Lenalidomide HCL Monohydrate IH | Manufacturing & Packing |
| 3. | Sofosbuvir IH | Manufacturing & Packing |
| 4. | Tenofovir Disproxil Phosphate IH | Manufacturing & Packing |
| 5. | Tenofovir Disproxil Succinate IH | Manufacturing & Packing |
| 6. | Tenofovir Alafenamide Fumarate IH | Manufacturing & Packing |
| 7. | Enzalutamide IH | Manufacturing & Packing |
| 8. | Rilpivirine HCl IH | Manufacturing & Packing |
| 9. | Velpatasvir IH | Manufacturing & Packing |
| 10. | Sunitinib IH | Manufacturing & Packing |


ITEM(S) Ten (10) ONLY

This certificate is being issued subject to condition that the firm shall obtained NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substance for the purpose of export only, as the above mentioned active substance is not approved for manufacture for sale in India


The Written Confirmation remains valid until: 02.07.2022


Signature

Stamp of the authority and date



27 JUN 2019

% 8705
25/06/19

25-6-19